New Drug Product: Imbruvica

Treatment of patients with mantle cell lymphoma (MCL) or chronic lymphocytic leukemia (CLL) who have received at least one prior therapy.

Streptococcus bovis and CRC

Some research has suggested that only certain subspecies of S. bovis may be implicated in colorectal cancer.

Underestimating Prostate Cancer Tumors

A study reports that testing severely underestimated the aggressiveness of tumors in patients with prostate cancer.

High-Fat Diet and Breast Cancer Risk

Eating foods high in saturated fat may increase breast cancer risk, says new research.

Hypertension and Kidney Cancer Risk

A new study found that the risk of kidney cancer climbs as systolic blood pressure increases.

Menstrual Cycles, Ovarian Cancer

Irregular menstrual cycles may be an early marker of ovarian cancer risk.

Women 70+: No Routine Mammograms

Mammogram breast cancer screenings for women aged ≥70 may cause more harm than good.

FDA-Approved Prostate Cancer Treatments

Review this new chart on FDA-approved prostate cancer treatments for quick information when you need it.


Cancer 'Vaccine' Passes Early Hurdle

Cancer 'Vaccine' Passes Early Hurdle

Early progress has been made in developing a treatment that might one day help the immune system defend itself against cancer.

Arzerra Gains New Indication

Arzerra Gains New Indication

The FDA has approved a new indication for Arzerra (ofatumumab; GlaxoSmithKline) to use in combination with chlorambucil, for the treatment of previously untreated patients with chronic lymphocytic leukemia (CLL), for whom fludarabine-based therapy is considered inappropriate.

Volasertib Designated Orphan Drug for Acute Myeloid Leukemia

The FDA has granted Orphan Drug designation to volasertib (Boehringer Ingelheim) for acute myeloid leukemia (AML).

AbbVie Launches Veliparib Trial for NSCLC

AbbVie announced the initiation of a Phase 3 trial evaluating the safety and efficacy of veliparib (ABT-888) in patients with previously untreated locally advanced or metastatic squamous non-small cell lung cancer (NSCLC).

Rates of Interval Cancers in CRC Patients

Rates of Interval Cancers in CRC Patients

Six percent of patients with colorectal cancer (CRC) have interval cancers, which develop within six to 60 months of colonoscopy.


Make prescribing decisions with our comparative charts and treatment algorithms.


Quickly and accurately perform clinical calculations.

Patient Information Fact Sheets

Download or print easy-to-read disease leaflets for your patients.

Featured courses from mycme

Red flag - Unintentional weight lossExternal web site

Red flag - Unintentional weight loss

0.50 Credits

Clinical Review - Acute myeloid leukaemiaExternal web site

Clinical Review - Acute myeloid leukaemia

2.50 Credits

Clinical Review: Diffuse large B-cell lymphomaExternal web site

Clinical Review: Diffuse large B-cell lymphoma

2.50 Credits
More myCME courses »

Sign Up for Free e-newsletters